



Regd. Office &amp; Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R. Dist. - 501 511. (T.S) INDIA.

Admin Office : 3-11-451, L B Nagar, Hyderabad - 500074

E-mail : concorddrugsLtd@gmail.com

Ph.No : +91 9052779505

Website : www.concorddrugs.in

Date: 08.08.2025

To,  
**BSE Limited,**  
Phiroze Jeejeebhoy Towers,  
Dalal St, Fort, Mumbai,  
Maharashtra 400001

**Scrip Code: 538965****Sub: Outcome of Board Meeting held on 08<sup>th</sup> August, 2025 pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.****Dear Sir/Madam,**

Further to our intimation dated 01<sup>st</sup> August, 2025, the Board of Directors, at its meeting held today, has approved the "Un-audited (Standalone and Consolidated) financial results" of the Company for the first quarter ended 30th June 2025 together with the Limited Review Reports as reviewed by the Audit Committee.

Further, the financial results are also available on the website of the Company at (<https://concorddrugs.in/investor-relations>) and on the website of BSE Ltd viz. [www.bseindia.com](http://www.bseindia.com).

The financial results will also be published in the newspaper as per the requirement and in the format prescribed under SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

Board Meeting commenced at 04:45 PM and concluded at 05:15 PM.

This is for the information and record.

Thanking you  
Yours Sincerely,

**For Concord Drugs Limited**

Seelam  
Nagi Reddy

Digitally signed by  
Seelam Nagi Reddy  
Date: 2025.08.08  
17:26:01 +05'30'

**NAGI REDDY SEELAM**  
**Chairman & Managing Director**  
(DIN: 01764665)

## STATEMENT OF UN AUDITED Consolidated FINANCIAL RESULTS FOR THE QUARTER ENDED 30th June 2025

[Rs. in Lakhs]

| Particulars   | Quarterly ended           |                        |                           |                        |
|---|---------------------------|------------------------|---------------------------|------------------------|
|   | 30-Jun-25<br>(Un Audited) | 31-Mar-25<br>(Audited) | 30-Jun-24<br>(Un Audited) | 31-Mar-25<br>(Audited) |
| <b>I Revenue from Operations</b>  |                           |                        |                           |                        |
| a. Net sales from Operations  | 1,360.64                  | 1,039.17               | 1,169.29                  | 4,524.47               |
| b. Other Operating Income   | -                         | 0.48                   | -                         | 1.44                   |
| <b>II Other Income</b>  |                           |                        |                           |                        |
| <b>III Total Revenue (I+II)</b>   | <b>1,360.64</b>           | <b>1,039.65</b>        | <b>1,169.29</b>           | <b>4,525.91</b>        |
| <b>IV Expenses</b>  |                           |                        |                           |                        |
| a. Cost of Material Consumed  | 1,081.22                  | 865.11                 | 866.98                    | 3,581.09               |
| b. Changes in Inventories of finished goods, work-in-progress and stock-in-trade  | 60.64                     | -74.49                 | 35.16                     | -58.05                 |
| c. Employees Benefit Expenses   | 88.60                     | 123.83                 | 145.81                    | 463.45                 |
| d. Finance Costs  | 49.00                     | 61.10                  | 45.28                     | 202.67                 |
| e. Depreciation and Amortisation expense  | 36.78                     | 37.76                  | 33.86                     | 143.08                 |
| f. Other expenses   | 28.55                     | 20.54                  | 38.11                     | 124.54                 |
| <b>Total Expenses</b>   | <b>1,344.81</b>           | <b>1,033.85</b>        | <b>1,165.20</b>           | <b>4,456.78</b>        |
| <b>Profit/ (Loss) before Exceptional item and tax (III-IV)</b>  | <b>15.83</b>              | <b>5.80</b>            | <b>4.09</b>               | <b>69.13</b>           |
| <b>V Exceptional Items</b>  |                           |                        |                           |                        |
|   | 15.83                     | 5.80                   | 4.09                      | 69.13                  |
| <b>VI Profit/ (Loss) before tax (V-VI)</b>  | <b>4.07</b>               | <b>1.90</b>            | <b>1.36</b>               | <b>35.52</b>           |
| <b>VII Tax Expense:</b>   |                           |                        |                           |                        |
| a. Current tax  | 5.34                      | 0.31                   | 2.83                      | 20.29                  |
| b. Deferred tax charge/credit   | -1.27                     | 1.59                   | -1.47                     | 15.23                  |
| <b>IX Profit/ (Loss) for the period (VII-VIII)</b>  | <b>11.77</b>              | <b>3.90</b>            | <b>2.73</b>               | <b>33.61</b>           |
| <b>X Other Comprehensive Income</b>   |                           |                        |                           |                        |
| Items that will not be reclassified to profit or loss   | -                         | -                      | -                         | -                      |
| <b>Total Comprehensive Income for the period (comprising profit and other comprehensive income for the period) (IX+X)</b> | <b>11.77</b>              | <b>3.90</b>            | <b>2.73</b>               | <b>33.61</b>           |
| <b>XI Paid up Capital</b>   | <b>1,000.00</b>           | <b>1,000.00</b>        | <b>1,000.00</b>           | <b>1,000.00</b>        |
| (Face value of the share- Rs. 10 each)  |                           |                        |                           |                        |
| <b>Other Equity</b>   | <b>2,422.50</b>           | <b>2,411.36</b>        | <b>2,382.95</b>           | <b>2,411.36</b>        |
| <b>XII Earnings per share (of Rs. 10 each) (in Rupees)</b>  |                           |                        |                           |                        |
| a. Basic (in Rs)  | 0.12                      | 0.04                   | 0.03                      | 0.34                   |
| b. Diluted (in Rs)  | 0.12                      | 0.04                   | 0.03                      | 0.34                   |

## Notes:

- The financial results of the company have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued there under.
- The above Consolidated financial results as reviewed by the audit committee have been approved by Board of Directors at its meeting held on 08.08.2025
- Figures of the corresponding previous periods are regrouped and reclassified wherever considered necessary to correspond with current period's presentation.
- The results are also available on the website of the Company [www.concorddrugs.in](http://www.concorddrugs.in)

Place: Hyderabad

Date: 08.08.2025



## STATEMENT OF Un -AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30th June 2025

[Rs. in Lakhs]

| Particulars   | Quarterly ended           |                         |                           |                        |
|---|---------------------------|-------------------------|---------------------------|------------------------|
|   | 30-Jun-25<br>(un Audited) | 31-Mar-25<br>( Audited) | 30-Jun-24<br>(un Audited) | 31-Mar-25<br>(Audited) |
| <b>I Revenue from Operations</b>  |                           |                         |                           |                        |
| a. Net sales from Operations  | 1,338.35                  | 796.40                  | 635.32                    | 3,693.21               |
| b. Other Operating Income   | -                         | 0.48                    | -                         | 1.44                   |
| <b>II Other Income</b>  |                           |                         |                           |                        |
| <b>III Total Revenue (I+II)</b>   | <b>1,338.35</b>           | <b>796.88</b>           | <b>635.32</b>             | <b>3,694.65</b>        |
| <b>IV Expenses</b>  |                           |                         |                           |                        |
| a. Cost of Material Consumed  | 1,068.92                  | 604.42                  | 387.92                    | 2,822.46               |
| b. Changes in Inventories of finished goods, work-in-progress and stock-in-trade  | 60.64                     | -74.49                  | 35.16                     | -58.05                 |
| c. Employees Benefit Expenses   | 87.11                     | 153.31                  | 105.19                    | 439.13                 |
| d. Finance Costs  | 41.99                     | 53.48                   | 37.03                     | 171.84                 |
| e. Depreciation and Amortisation expense  | 36.55                     | 37.45                   | 33.54                     | 141.80                 |
| f. Other expenses   | 27.94                     | 20.64                   | 33.83                     | 113.34                 |
| <b>Total Expenses</b>   | <b>1,323.15</b>           | <b>794.81</b>           | <b>632.67</b>             | <b>3,630.52</b>        |
| <b>Profit/ (Loss) before Exceptional item and tax (III-IV)</b>  | <b>15.20</b>              | <b>2.07</b>             | <b>2.65</b>               | <b>64.13</b>           |
| <b>V Exceptional Items</b>  | -                         | -                       | -                         | -                      |
| <b>VI Profit/ (Loss) before tax (V-VI)</b>  | <b>15.20</b>              | <b>2.07</b>             | <b>2.65</b>               | <b>64.13</b>           |
| <b>VII Tax Expense:</b>   | <b>4.06</b>               | <b>1.26</b>             | <b>1.47</b>               | <b>34.56</b>           |
| <b>VIII a. Current tax</b>  | <b>5.15</b>               | <b>-0.67</b>            | <b>2.39</b>               | <b>18.99</b>           |
| <b>0 b. Deferred tax charge/credit</b>  | <b>-1.09</b>              | <b>1.93</b>             | <b>-0.92</b>              | <b>15.57</b>           |
| <b>IX Profit/ (Loss) for the period (VII-VIII)</b>  | <b>11.14</b>              | <b>0.81</b>             | <b>1.18</b>               | <b>29.57</b>           |
| <b>X Other Comprehensive Income</b>   | -                         | -                       | -                         | -                      |
| Items that will not be reclassified to profit or loss   | -                         | -                       | -                         | -                      |
| <b>Total Comprehensive Income for the period (comprising profit and other comprehensive income for the period) (IX+X)</b> | <b>11.14</b>              | <b>0.81</b>             | <b>1.18</b>               | <b>29.57</b>           |
| <b>XI Paid up Capital</b>   | <b>1,000.00</b>           | <b>1,000.00</b>         | <b>1,000.00</b>           | <b>1,000.00</b>        |
| (Face value of the share- Rs. 10 each)  |                           |                         |                           |                        |
| <b>Other Equity</b>   | <b>2,422.50</b>           | <b>2,411.36</b>         | <b>2,382.95</b>           | <b>2,411.36</b>        |
| <b>XII Earnings per share (of Rs. 10 each) (in Rupees)</b>  |                           |                         |                           |                        |
| <b>XIII a. Basic (in Rs)</b>  | <b>0.11</b>               | <b>0.01</b>             | <b>0.01</b>               | <b>0.30</b>            |
| <b>b. Diluted (in Rs)</b>   | <b>0.11</b>               | <b>0.01</b>             | <b>0.01</b>               | <b>0.30</b>            |

## Notes:

|   |   |
|---|---|
| 1 | The financial results of the company have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued there under. |
| 2 | The above standalone financial results as reviewed by the audit committee have been approved by Board of Directors at its meeting held on 08.08.2025  |
| 3 | Figures of the corresponding previous periods are regrouped and reclassified wherever considered necessary to correspond with current period's presentation.  |
| 4 | The results are also available on the website of the Company <a href="http://www.concorddrugs.in">www.concorddrugs.in</a>   |

Place: Hyderabad

Date: 08.08.2025





# PUNDARIKASHYAM AND ASSOCIATES

## CHARTERED ACCOUNTANTS

# 1-8-435/436, 2nd Floor, Durga Towers, Beside Rasoolpura Metro Station, Begumpet,  
Hyderabad, Telangana - 500016. Cell : 9440464339, Ph : 040-35175033

E-mail : info@pkas.in / infoong@pkas.in

GSTIN : 36AAJFP6218J1ZY

- Branches : 1. Door No. 76-14-243/1A, Vasavi Kalyana Mandapam Road, Sivalayam Centre, Bhavani Puram, Vijayawada - 12.  
2. 7-310, Shop No. 204, Padma Towers, South Bypass Road, Ongole, 523001.  
3. Flat No. 202, 2nd Floor, Vijaya Ganapathi Nilayam, Ayyappa Nagar, Murali Nagar, Near Masjid Junction,  
Visakhapatnam, Andhra Pradesh - 530007.

### Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

#### To the Board of Directors of Concord Drugs Limited,

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Concord Drugs Limited ('the company') for the quarter ended 30 June 2025, being submitted by the Company pursuant to the requirements of the regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time.
2. The statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the act'), SEBI circular CIR/CFD/FAC/62/2016, dated 5 July 2016, (hereinafter referred to as 'the SEBI Circular'), and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act, the SEBI Circular, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Pundarikashyam And Associates**  
**Chartered Accountants**  
**FRN:011330S**

*B. Surya Prakasa Rao*

**B Surya Prakasa Rao**  
**(Partner)**

**MNo: 205125**

**UDIN No: 25205125BMTADY3304.**



**Place: Hyderabad**  
**Date: 08.08.2025**



# PUNDARIKASHYAM AND ASSOCIATES

## CHARTERED ACCOUNTANTS

# 1-8-435/436, 2nd Floor, Durga Towers, Beside Rasoolpura Metro Station, Begumpet,  
Hyderabad, Telangana - 500016. Cell : 9440464339, Ph : 040-35175033

E-mail : info@pkas.in / infoong@pkas.in

GSTIN : 36AAJFP6218J1ZY

- Branches : 1. Door No. 76-14-243/1A, Vasavi Kalyana Mandapam Road, Sivalayam Centre, Bhavani Puram, Vijayawada - 12.  
2. 7-310, Shop No. 204, Padma Towers, South Bypass Road, Ongole, 523001.  
3. Flat No. 202, 2nd Floor, Vijaya Ganapathi Nilayam, Ayyappa Nagar, Murali Nagar, Near Masjid Junction,  
Visakhapatnam, Andhra Pradesh - 530007.

### Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Concord Drugs Limited,

1. We have reviewed the accompanying statement of Consolidated unaudited financial results ('the Statement') of Concord Drugs Limited ('the company') for the quarter ended 30 June 2025, being submitted by the Company pursuant to the requirements of the regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time.
2. The statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the act'), SEBI circular CIR/CFD/FAC/62/2016, dated 5 July 2016, (hereinafter referred to as 'the SEBI Circular'), and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



4. The Statement includes the results of the following entities:  
Proton Remedies Private Limited


5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act, the SEBI Circular, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. The accompanying Statement includes the unaudited interim financial results and other financial information, in respect of:

one subsidiary, whose unaudited interim financial results include total revenues of Rs 40.44 lakhs, total net profit after tax of Rs.0.62 lakhs, for the quarter ended June 30, 2025, as considered in the Statement which have been reviewed by their respective independent auditors. The independent auditor's reports on unaudited interim financial results and other financial information of these entities have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures in respect of this subsidiary is based solely on the report of such auditors and procedures performed by us as stated in paragraph 3 above. Our conclusion on the Statement in respect of matters stated in para above is not modified with respect to our reliance on the work done and the reports of the other auditors.

**For Pundarikashyam And Associates**  
**Chartered Accountants**  
**FRN:011330S**

*B. Surya Prakasa Rao*  
**B Surya Prakasa Rao**  
**(Partner)**  
**MNo: 205125**



**UDIN No : 25205125 BMIADZ7543.**

**Place: Hyderabad**

**Date: 08-08-2025.**



Regd. Office &amp; Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R. Dist. - 501 511. (T.S) INDIA.

Admin Office : 3-11-451, L B Nagar, Hyderabad - 500074

E-mail : concorddrugsttd@gmail.com

Ph.No : +91 9052779505

Website : www.concorddrugs.in

**B. STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE, QUALIFIED INSTITUTIONS PLACEMENT ETC.**

Not Applicable

**C. FORMAT FOR DISCLOSING OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES:**There is no default on loans and debt securities for the Quarter ended 30<sup>th</sup> June,2025.

| Sl.No | Particulars  | In Rs. |
|-------|--|--------|
| 1.    | Loans / revolving facilities like cash credit from banks / financial institutions          |        |
| A     | Total amount outstanding as on date  | 0      |
| B     | Of the total amount outstanding, amount of default as on date                              | 0      |
| 2.    | Unlisted debt securities i.e. NCDs and NCRPS   |        |
| A     | Total amount outstanding as on date  | 0      |
| B     | Of the total amount outstanding, amount of default as on date                              | 0      |
| 3.    | Total financial indebtedness of the listed entity including short- term and long-term debt | 0      |

**D. FORMAT FOR DISCLOSURE OF RELATED PARTY TRANSACTIONS (applicable only for half-yearly filings i.e., 2nd and 4th quarter):**

Not Applicable

**E. STATEMENT ON IMPACT OF AUDIT QUALIFICATIONS (FOR AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONG-WITH ANNUAL AUDITED FINANCIAL RESULTS (Standalone and Consolidated separately) (applicable only for Annual Filing i.e., 4th quarter):**

Not Applicable